Extending the Duration of First-line Chemotherapy in Metastatic Breast Cancer: a Perspective Review

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2011 Sep 30

PMID 21957429

Citations 8

Authors

Alessandra Gennari

Mauro DAmico

Davide Corradengo

Affiliations

Soon will be listed here.

Abstract

The treatment of metastatic breast cancer is mainly palliative, but optimal management might result in survival improvement as well. For this reason, many trials have attempted to optimize the therapeutic approach in this disease setting. Among the possible options, chemotherapy represents the backbone of the treatment and survival improvements that have been shown by the use of modern chemotherapeutic agents. Whereas the type of chemotherapy is generally dictated by patient characteristics and those of their disease, substantial controversy still remains on how long chemotherapy should be administered after disease control is achieved. In this review, we have analysed all available evidence on the duration of first-line chemotherapy in advanced breast cancer.

Citing Articles

Predictive Modeling of Long-Term Survivors with Stage IV Breast Cancer Using the SEER-Medicare Dataset.

Adam N, Wieder R Cancers (Basel). 2024; 16(23).

PMID: 39682219 PMC: 11640017. DOI: 10.3390/cancers16234033.

Towards Agility in Breast Cancer Treatment Principles as Adopted from Agile Software Engineering.

Odeh Y, Al-Balas M J Multidiscip Healthc. 2024; 17:1315-1341.

PMID: 38545433 PMC: 10968939. DOI: 10.2147/JMDH.S449465.

Breast cancer: insights in disease and influence of drug methotrexate.

Yang V, Gouveia M, Santos J, Koksch B, Amorim I, Gartner F RSC Med Chem. 2021; 11(6):646-664.

PMID: 33479665 PMC: 7578709. DOI: 10.1039/d0md00051e.

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S Support Care Cancer. 2017; 25(11):3295-3304.

PMID: 28842778 PMC: 5610660. DOI: 10.1007/s00520-017-3842-1.

Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature.

Banys-Paluchowski M, Schutz F, Ruckhaberle E, Krawczyk N, Fehm T Geburtshilfe Frauenheilkd. 2016; 76(5):525-534.

PMID: 27239061 PMC: 4873299. DOI: 10.1055/s-0042-105871.

References

Nooij M, de Haes J, Beex L, Wildiers J, KLIJN J, Becquart D . Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. Eur J Cancer. 2003; 39(5):614-21. DOI: 10.1016/s0959-8049(02)00869-9. View

Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P . Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005; 104(8):1742-50. DOI: 10.1002/cncr.21359. View

Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen H, Rose C, Overgaard M . Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer. 1993; 29A(4):527-31. DOI: 10.1016/s0959-8049(05)80145-5. View

Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D . Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011; 29(16):2144-9. DOI: 10.1200/JCO.2010.31.5374. View

Geels P, Eisenhauer E, Bezjak A, Zee B, Day A . Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000; 18(12):2395-405. DOI: 10.1200/JCO.2000.18.12.2395. View

Harris A, Cantwell B, Carmichael J, Wilson R, Farndon J, Dawes P . Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990; 335(8683):186-90. DOI: 10.1016/0140-6736(90)90277-c. View

. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol. 2000; 18(17):3115-24. DOI: 10.1200/JCO.2000.18.17.3115. View

FALKSON G, Gelman R, Pandya K, Osborne C, Tormey D, CUMMINGS F . Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998; 16(5):1669-76. DOI: 10.1200/JCO.1998.16.5.1669. View

Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V . Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006; 24(24):3912-8. DOI: 10.1200/JCO.2006.06.1812. View

10.

Muss H, Case L, Richards 2nd F, White D, Cooper M, Cruz J . Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991; 325(19):1342-8. DOI: 10.1056/NEJM199111073251904. View

11.

Chia S, Speers C, Dyachkova Y, Kang A, Malfair-Taylor S, Barnett J . The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007; 110(5):973-9. DOI: 10.1002/cncr.22867. View

12.

Bertelli G, Garrone O, Bertolotti L, Occelli M, Conforti S, Marzano N . Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology. 2005; 68(4-6):364-70. DOI: 10.1159/000086976. View

13.

Stockler M, Wilcken N, Coates A . Chemotherapy for metastatic breast cancer--when is enough enough?. Eur J Cancer. 1998; 33(13):2147-8. DOI: 10.1016/s0959-8049(97)00257-8. View

14.

Coates A, Gebski V, Bishop J, Jeal P, Woods R, Snyder R . Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987; 317(24):1490-5. DOI: 10.1056/NEJM198712103172402. View

15.

Alba E, Ruiz-Borrego M, Margeli M, Rodriguez-Lescure A, Sanchez-Rovira P, Ruiz A . Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. 2010; 122(1):169-76. DOI: 10.1007/s10549-010-0860-9. View

16.

Gregory R, Powles T, Chang J, Ashley S . A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer. 1998; 33(13):2194-7. DOI: 10.1016/s0959-8049(97)00396-1. View